{"id":"lurasidone-oral-capsule","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"8-12","effect":"Somnolence"},{"rate":"5-10","effect":"Parkinsonism"},{"rate":"5-8","effect":"Nausea"},{"rate":"5-10","effect":"Restlessness"},{"rate":"3-5","effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with additional activity at 5-HT1A receptors. This multi-target receptor profile is characteristic of atypical antipsychotics and helps modulate both dopaminergic and serotonergic neurotransmission implicated in psychosis and mood disorders. The oral capsule formulation allows for systemic delivery to achieve therapeutic CNS concentrations.","oneSentence":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors to reduce psychotic symptoms and mood disturbances.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:48.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder depression"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT03396068","phase":"PHASE3","title":"NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation","status":"UNKNOWN","sponsor":"NeuroRx, Inc.","startDate":"2019-12-01","conditions":"Bipolar Depression, Suicidal Ideation","enrollment":72},{"nctId":"NCT03402152","phase":"PHASE2, PHASE3","title":"NRX101 Glx Biomarker Validation Study","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-11-01","conditions":"Bipolar Depression, Suicidal Ideation","enrollment":8},{"nctId":"NCT02974010","phase":"PHASE2","title":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-01-15","conditions":"Bipolar Depression, Suicidal Ideas, Suicidal Ideation","enrollment":22},{"nctId":"NCT01833897","phase":"PHASE4","title":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-03","conditions":"Bipolar Disorder","enrollment":8},{"nctId":"NCT01074073","phase":"PHASE1","title":"Lithium Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Schizophrenia","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lurasidone Fixed Dose Combination","Latuda®","Latuda"],"phase":"phase_3","status":"active","brandName":"Lurasidone Oral Capsule","genericName":"Lurasidone Oral Capsule","companyName":"NeuroRx, Inc.","companyId":"neurorx-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors to reduce psychotic symptoms and mood disturbances. Used for Schizophrenia, Bipolar I disorder depression, Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}